Details of the Drug Combination

General Information of Drug Combination (ID: DCD8CR0)

Drug Combination Name

Taxol MK-5108

Indication

Disease Entry	Status	REF
Malignant melanoma	Investigative	[1]

Component Drugs

Taxol DMUOT9V

MK-5108 DMFGYKS

Small molecular drug

2D MOL

3D MOL is unavailable

3D MOL

High-throughput Screening Result

Testing Cell Line: SKMEL30

Zero Interaction Potency (ZIP) Score: 8.94

Bliss Independence Score: 7.65

Loewe Additivity Score: 3.1

LHighest Single Agent (HSA) Score: 9.11

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Taxol

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Pancreatic cancer	2C10	Phase 3	[4]
Gastric adenocarcinoma	2B72	Phase 2	[5]
Ovarian cancer	2C73	Phase 2	[5]

Taxol Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Modulator	[2]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[2]
------------------------------------------------------------------------------------

Indication(s) of MK-5108

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]

MK-5108 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Aurora kinase B (AURKB)	TT5LS6T	AURKB_HUMAN	Inhibitor	[7]
Aurora kinase A (AURKA)	TTPS3C0	AURKA_HUMAN	Inhibitor	[7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour	DCBWEPY	ES2	Investigative	[8]
Breast and ovarian cancer syndrome	DCY402E	UWB1289	Investigative	[9]
Breast and ovarian cancer syndrome	DC7Z562	UWB1289+BRCA1	Investigative	[9]
Breast carcinoma	DCU9KRX	OCUBM	Investigative	[9]
Carcinoma	DCNS58T	EFM192B	Investigative	[9]
Carcinoma	DCLFAOP	MDAMB436	Investigative	[9]
Colon adenocarcinoma	DCNN52G	LOVO	Investigative	[9]
Invasive ductal carcinoma	DCEJTCT	T-47D	Investigative	[9]
Adenocarcinoma	DC6EEQ1	CAOV3	Investigative	[1]
Adenocarcinoma	DC0U3B1	A427	Investigative	[1]
Adenocarcinoma	DCWJK29	NCIH1650	Investigative	[1]
Adenocarcinoma	DC8X8MF	NCIH2122	Investigative	[1]
Adenocarcinoma	DCAY37I	NCIH23	Investigative	[1]
Adenocarcinoma	DCLWNDA	NCIH520	Investigative	[1]
Adenocarcinoma	DCXOZI7	COLO320DM	Investigative	[1]
Adenocarcinoma	DCCX2OC	DLD1	Investigative	[1]
Adenocarcinoma	DCAZ0ZG	SW-620	Investigative	[1]
Amelanotic melanoma	DCF7PIV	A2058	Investigative	[1]
Germ cell tumour	DC6AI7I	PA1	Investigative	[1]
Large cell lung carcinoma	DC6KJ76	NCI-H460	Investigative	[1]
Malignant melanoma	DCW9M6D	RPMI7951	Investigative	[1]
Mesothelioma	DC59QWU	MSTO	Investigative	[1]
Non small cell carcinoma	DC4ZLGG	SKMES1	Investigative	[1]
Ovarian endometrioid adenocarcinoma	DCU846O	A2780	Investigative	[1]
Prostate carcinoma	DCG0S7C	VCAP	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 25 DrugCom(s)

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	ClinicalTrials.gov (NCT00543387) Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4). U.S. National Institutes of Health.
7	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
8	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
9	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.